Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gyre Therapeutics (GYRE) Notes Payables (2016 - 2017)

Historic Notes Payables for Gyre Therapeutics (GYRE) over the last 3 years, with Q4 2017 value amounting to $5.1 million.

  • Gyre Therapeutics' Notes Payables fell 7379.27% to $5.1 million in Q4 2017 from the same period last year, while for Dec 2017 it was $5.1 million, marking a year-over-year decrease of 7379.27%. This contributed to the annual value of $5.1 million for FY2017, which is 7379.27% down from last year.
  • As of Q4 2017, Gyre Therapeutics' Notes Payables stood at $5.1 million, which was down 7379.27% from $5.5 million recorded in Q3 2017.
  • In the past 5 years, Gyre Therapeutics' Notes Payables ranged from a high of $34.8 million in Q3 2015 and a low of $5.1 million during Q4 2017
  • Moreover, its 3-year median value for Notes Payables was $24.5 million (2016), whereas its average is $20.8 million.
  • Per our database at Business Quant, Gyre Therapeutics' Notes Payables tumbled by 1468.87% in 2016 and then crashed by 8150.13% in 2017.
  • Quarter analysis of 3 years shows Gyre Therapeutics' Notes Payables stood at $33.7 million in 2015, then crashed by 42.5% to $19.4 million in 2016, then plummeted by 73.79% to $5.1 million in 2017.
  • Its last three reported values are $5.1 million in Q4 2017, $5.5 million for Q3 2017, and $5.8 million during Q2 2017.